PREVENT: PeRomEter Visualization to ENd Treatment-related Lymphedema

Primary Objectives:

• To determine the effectiveness of prospective, intensive lymphedema screening in the postoperative setting using a perometer for reducing the cumulative incidence of grade lymphedema among breast cancer patients after ALND compared to routine screening. Secondary Objectives:
• To estimate the direct costs associated with the Lymphedema Screening Initiative
• To determine the association of the Initiative on patient productivity
• To determine patient satisfaction with the Lymphedema Initiative in the context of their cancer care
• To determine patient understanding of lymphedema-associated symptoms
• To determine patient self-reported compliance with treatments and measures to prevent lymphedema
• To determine the incidence of breast cancer-related lymphedema among a cohort of breast cancer patients treated with ALND To analyze clinical and pathological features associated with the development of lymphedema

Inclusion criteria

a Cohort A:

• Breast cancer patients with a baseline (preoperative perometer measurements) who have undergone axillary lymph node dissection
• English speaker
• Patients who participate in Cohort A will be eligible for enrollment in Cohort

b Cohort I:

• Breast cancer patients who have undergone axillary lymph node dissection who have a clinic visit in the Nellie B. Connally Breast Center approximately 12 months (+/- 4 months) following axillary lymph node dissection
• English speaker

c Cohort II:

• Breast cancer patients who have undergone axillary lymph node dissection who are having a follow-up visit in the Nellie B. Connally Breast Center within 0-6 months following surgery who intend to continue follow-up care at MD Anderson
• English speaker

Exclusion criteria

Inability to complete a self-administered questionnaire